PrognomiQ's Latest Research Demonstrates the Potential of its Multi-omics Liquid Biopsy Platform in Early-Stage Detection of Lung Cancer
SAN MATEO, Calif., Jan. 8, 2024 /PRNewswire/ -- PrognomiQ – a healthcare company focused on harnessing the power of multi-omics data to transform the early detection, treatment selection and recurrence monitoring of cancer and other complex diseases – today announced promising results from the largest, deep multi-omics study conducted to date. The study, published online in medRxiv, focused on subjects at risk for lung cancer, demonstrating the power of multi-omics to deliver both high sensitivity and high specificity in the detection of early-stage lung cancer.
- The study, published online in medRxiv , focused on subjects at risk for lung cancer, demonstrating the power of multi-omics to deliver both high sensitivity and high specificity in the detection of early-stage lung cancer.
- These encouraging data stem from a 2,513-subject case-control study which analyzed the molecular differences between the peripheral blood plasma of lung cancer subjects and non-cancer controls, many of whom were at high-risk for lung cancer.
- Given the focus on high-risk populations in this study, the team focused on prioritizing high sensitivity, particularly for early-stage cancer.
- These findings add to the body of research previously presented in 2023 on lung cancer detection at both the American College of Chest Physicians (CHEST) and the World Conference on Lung Cancer (WCLC), and on pancreatic cancer detection at the American Association of Cancer Research (AACR) annual conferences.